Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ANIX NASDAQ:LONA NASDAQ:TPST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.58-0.3%$4.70$3.35▼$17.94$78.32M4.47185,114 shs111,385 shsANIXAnixa Biosciences$2.40-2.4%$2.79$2.40▼$5.46$82.48M0.59103,640 shs108,164 shsLONAAthira Pharma$8.46-1.5%$9.61$2.85▼$14.21$80.69M1.9736,988 shs20,559 shsTPSTTempest Therapeutics$1.27$1.76$1.23▼$12.23$18.81M-1.85121,873 shs71,779 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-2.45%-10.03%-34.01%-38.00%-69.60%ANIXAnixa Biosciences-0.81%-8.89%-18.00%-17.45%-10.87%LONAAthira Pharma+4.50%-7.53%-14.44%+33.59%+858,999,900.00%TPSTTempest Therapeutics0.00%-12.41%-36.18%-47.08%-84.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$3.58-0.3%$4.70$3.35▼$17.94$78.32M4.47185,114 shs111,385 shsANIXAnixa Biosciences$2.40-2.4%$2.79$2.40▼$5.46$82.48M0.59103,640 shs108,164 shsLONAAthira Pharma$8.46-1.5%$9.61$2.85▼$14.21$80.69M1.9736,988 shs20,559 shsTPSTTempest Therapeutics$1.27$1.76$1.23▼$12.23$18.81M-1.85121,873 shs71,779 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-2.45%-10.03%-34.01%-38.00%-69.60%ANIXAnixa Biosciences-0.81%-8.89%-18.00%-17.45%-10.87%LONAAthira Pharma+4.50%-7.53%-14.44%+33.59%+858,999,900.00%TPSTTempest Therapeutics0.00%-12.41%-36.18%-47.08%-84.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70450.28% UpsideANIXAnixa Biosciences 2.25Hold$8.50254.17% UpsideLONAAthira Pharma 2.40Hold$15.0077.30% UpsideTPSTTempest Therapeutics 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest TPST, ANIX, AARD, and LONA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/14/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/8/2026ANIXAnixa Biosciences D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.004/2/2026TPSTTempest Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$4.90 per shareN/AANIXAnixa Biosciences$210K383.20N/AN/A$0.42 per share5.71LONAAthira PharmaN/AN/AN/AN/A$2.98 per shareN/ATPSTTempest TherapeuticsN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/AANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%6/10/2026 (Estimated)LONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/ATPSTTempest Therapeutics-$26.26M-$6.01N/AN/AN/AN/A-355.61%-121.21%8/10/2026 (Estimated)Latest TPST, ANIX, AARD, and LONA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/14/2026Q1 2026TPSTTempest Therapeutics-$0.28-$2.53-$2.25-$2.53N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/30/2026Q4 2025TPSTTempest Therapeutics-$0.62-$0.62N/A-$0.62N/AN/A3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/ATPSTTempest TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06ANIXAnixa BiosciencesN/A12.1812.18LONAAthira PharmaN/A10.3810.38TPSTTempest TherapeuticsN/A0.740.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AANIXAnixa Biosciences29.13%LONAAthira Pharma57.12%TPSTTempest Therapeutics22.52%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AANIXAnixa Biosciences26.40%LONAAthira Pharma25.73%TPSTTempest Therapeutics6.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/AANIXAnixa Biosciences533.53 million24.68 millionOptionableLONAAthira Pharma409.39 million6.98 millionN/ATPSTTempest Therapeutics2014.81 million13.88 millionNo DataTPST, ANIX, AARD, and LONA HeadlinesRecent News About These CompaniesTempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | quiverquant.comQTempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of DirectorsJune 4, 2026 | globenewswire.comTempest Therapeutics Announces Resignation of Board DirectorMay 29, 2026 | tipranks.comTempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term WarrantsMay 29, 2026 | quiverquant.comQTempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross ProceedsMay 29, 2026 | globenewswire.comTempest Therapeutics Announces Multiple Board Director ResignationsMay 22, 2026 | tipranks.comTempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 15, 2026 | finanznachrichten.deTempest Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 14, 2026 | globenewswire.comTempest Presents Clinical Update at ISCT 2026 Annual MeetingMay 6, 2026 | globenewswire.comTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingApril 29, 2026 | globenewswire.comTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TApril 22, 2026 | globenewswire.comTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsApril 14, 2026 | globenewswire.comNew Strong Buy Stocks for April 10thApril 10, 2026 | zacks.comAnalysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST)April 1, 2026 | theglobeandmail.comTempest Reports Year End 2025 Financial Results and Provides Business UpdateMarch 30, 2026 | globenewswire.comTempest Therapeutics (NASDAQ:TPST) CEO Matthew Angel Acquires 231,482 SharesMarch 26, 2026 | insidertrades.comTempest Therapeutics Announces Up To $6 Million Private PlacementMarch 23, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 12, 2026 | finanznachrichten.deTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026March 11, 2026 | globenewswire.comTempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026February 26, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTPST, ANIX, AARD, and LONA Company DescriptionsAardvark Therapeutics NASDAQ:AARD$3.58 -0.01 (-0.28%) Closing price 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.56%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Anixa Biosciences NASDAQ:ANIX$2.40 -0.06 (-2.44%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Athira Pharma NASDAQ:LONA$8.46 -0.13 (-1.51%) Closing price 03:59 PM EasternExtended Trading$8.44 -0.03 (-0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Tempest Therapeutics NASDAQ:TPST$1.27 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
